Pharmaceutical Health Services Research, University of Maryland Baltimore, Baltimore, Maryland, USA
Pharmaceutical Health Services Research, University of Maryland Baltimore, Baltimore, Maryland, USA.
J Med Ethics. 2023 Feb;49(2):87-91. doi: 10.1136/medethics-2021-107436. Epub 2022 Apr 1.
The SARS-CoV-2 (COVID-19) pandemic continues to expose underlying inequities in healthcare for black, indigenous and Latinx communities in the USA. The gaps in equitable care for communities of colour transcend the diagnosis, treatment and vaccinations related to COVID-19. We are experiencing a continued gap across racial and socioeconomic lines for those who suffer prolonged effects of COVID-19, also known as 'Long COVID-19'. What we know about the treatment for Long COVID-19 so far is that it is complex, requires a multidisciplinary approach and there is still much research needed to fully understand the effects. In this paper, we discuss pragmatic considerations for including affected communities, relevant stakeholders, and leaders from communities of colour in the planning and implementation of Long COVID-19 research.
SARS-CoV-2（COVID-19）大流行继续暴露了美国黑人和拉丁裔社区医疗保健方面的基本不平等现象。在与 COVID-19 相关的诊断、治疗和疫苗接种方面，有色人种社区的公平护理差距依然存在。在那些遭受 COVID-19 长期影响（也称为“长 COVID-19”）的人群中，我们仍然存在着持续的种族和社会经济差距。到目前为止，我们对长 COVID-19 的治疗方法了解甚少，它很复杂，需要多学科的方法，仍需要大量的研究来全面了解其影响。在本文中，我们讨论了在规划和实施长 COVID-19 研究时，将受影响社区、相关利益攸关方和有色人种社区的领导人纳入其中的务实考虑因素。
